Encouraging Pre-Clinical Data Presented at US Cancer Meeting
Filed with ASX · · 2 pages · English
Novel compound PTX-100 shown to decrease multiple myeloma tumours, improve median survival times Data to be presented at American Association for Cancer Research Annual Meeting Melbourne, Australia – 21 April 2015– Prescient Therapeutics (ASX: PTX), a clinical stage oncology company, will announce today highly encouraging data from a pre-clinical trial of its novel compound PTX-100 (formerly k
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- PTX-200 Breast Cancer Trial Progresses
- Steven Yatomi-Clarke Appointed CEO
- December 2015 Appendix 4C - Quarterly
- Virax secures $3 million placement
- Virax close out of VIR201 HIV Vaccine Phase IIa Trial
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics